What is the recommended diagnostic work‑up and treatment plan for a patient with interstitial lung disease?

Diagnostic Work-Up and Treatment Plan for Interstitial Lung Disease

Initial Diagnostic Evaluation

High-resolution computed tomography (HRCT) is the gold-standard imaging test and must be performed in all patients with suspected ILD, achieving 95.7% sensitivity for disease involving ≥20% of lung parenchyma. 1

Clinical Assessment

• Evaluate for dyspnea on exertion and non-productive cough, recognizing that up to 90% of patients with early ILD may be asymptomatic, making symptom absence unreliable for excluding disease 1, 2
• Auscultate for fine, dry "Velcro-type" end-inspiratory crackles, present in >80% of idiopathic pulmonary fibrosis patients, though sensitivity is only moderate for early disease 1, 3
• Examine for digital clubbing (present in 25-50% of IPF cases), cyanosis in advanced disease, and signs of right heart failure including peripheral edema and elevated jugular venous pressure 1
• Document comprehensive occupational and environmental exposure history (mold, air pollution, occupational dusts, fumes, vapors) as these interact with genetic susceptibility to drive ILD development 1
• Screen systematically for connective tissue disease symptoms, as CTD-associated ILD accounts for 25% of all ILD cases 1, 4

Laboratory Testing

• Complete blood count with differential, C-reactive protein, serum creatinine, and liver function tests 1
• Autoimmune serologies: anti-nuclear antibodies, rheumatoid factor, anti-citrullinated cyclic peptide antibodies, and anti-topoisomerase (Scl-70) 1, 2
• For newborns with severe or rapidly progressive disease, or family history of ILD, genetic testing for SFTPB, SFTPC, and ABCA3 mutations is strongly recommended 5

Pulmonary Function Testing

• Spirometry to identify restrictive pattern (decreased FVC), total lung capacity (TLC) to confirm restriction, and diffusing capacity (DLCO) to assess gas exchange impairment are mandatory baseline tests 1, 3
• Recognize that baseline FVC <80% has only 47.5% sensitivity for detecting ILD, emphasizing the primacy of imaging over spirometry alone 1
• Perform 6-minute walk test with continuous oxygen saturation monitoring to detect exercise-induced desaturation and establish baseline exercise capacity 1, 2

HRCT Imaging Protocol

• HRCT acquisition must include inspiratory prone and supine end-expiratory images with slice thickness ≤2 mm 1
• Identify specific patterns:
  • Usual interstitial pneumonia (UIP): subpleural reticulation, traction bronchiectasis, honeycombing (mandatory for definite UIP), basal-peripheral distribution 1, 3
  • Non-specific interstitial pneumonia (NSIP): ground-glass opacities with reticulation and more uniform distribution 1
• Prominent diffuse ground-glass attenuation or mosaic-pattern ground-glass argues against UIP 1

Cardiovascular Evaluation

• Echocardiography is strongly recommended in the initial work-up to rule out structural cardiovascular disease and pulmonary hypertension, which is present in up to 85% of patients with end-stage fibrotic ILD and portends worse prognosis 5, 1, 4

Tissue Diagnosis Strategy

When HRCT demonstrates a definite UIP pattern in the appropriate clinical context, invasive sampling (surgical lung biopsy, transbronchial biopsy, or cryobiopsy) is not indicated. 1, 3

When Biopsy Is Needed

• Transbronchial lung cryobiopsy (TBLC) is the first-line biopsy method when HRCT and clinical findings are insufficient for definitive diagnosis, providing larger samples with fewer crush artifacts and lower complication rates than surgical biopsy 1, 3
• TBLC yields unclassifiable results in 17.2% of cases versus 1.3% for surgical lung biopsy 1
• Surgical lung biopsy via video-assisted thoracoscopy (VATS) should be reserved for rapidly progressive ILD or when TBLC results are nondiagnostic 5, 1
• Lung biopsy specimens require separate portions for formalin fixation (histopathology), microbiologic culture, freezing (immunofluorescence), and electron microscopy 5

Bronchoalveolar Lavage (BAL)

• Consider flexible bronchoscopy with BAL to exclude infection or airway abnormalities 5
• BAL cellular analysis is not recommended in patients with a UIP pattern on HRCT 1
• Interpret BAL differential counts:
  • Lymphocytes >25%: suggests granulomatous disease (sarcoidosis, hypersensitivity pneumonitis), cellular NSIP, drug-induced lung injury 1
  • Lymphocytes >50%: strongly suggests hypersensitivity pneumonitis or cellular NSIP 1
  • Eosinophils >25%: virtually diagnostic of acute or chronic eosinophilic pneumonia 1
  • CD4+/CD8- ratio >4: highly specific for sarcoidosis 1

Multidisciplinary Discussion

A formal multidisciplinary discussion involving pulmonologists, radiologists, and pathologists experienced in ILD is mandatory to integrate clinical, radiologic, and pathologic data for optimal diagnostic accuracy. 1, 3

• MDD categorizes diagnostic confidence into four tiers: confident diagnosis (>90% certainty), provisional high confidence (70-90%), provisional low confidence (50-70%), and unclassifiable ILD (<50% certainty) 1
• Complex or ambiguous cases should be referred to expert ILD centers 1

Treatment Algorithm

Idiopathic Pulmonary Fibrosis (IPF) with Definite UIP

Antifibrotic therapy with either nintedanib or pirfenidone must be started at the time of diagnosis, reducing annual FVC decline by approximately 44-57%. 1, 4

• Both agents have comparable efficacy; choice should be guided by individual tolerability and comorbidities 1, 3
• Immunosuppression is contraindicated in IPF and may be harmful 3
• Triple therapy with prednisone, azathioprine, and N-acetylcysteine is strongly contraindicated 1

Connective Tissue Disease-Associated ILD (CTD-ILD)

Mycophenolate is the preferred first-line immunosuppressive agent for all CTD-ILD subtypes, irrespective of radiologic pattern. 1, 3

• Alternative first-line options include azathioprine, rituximab, and cyclophosphamide 1, 3
• Rituximab may be selected as initial therapy for rheumatoid arthritis-ILD with active inflammatory arthritis, as it reduces mortality and controls systemic disease activity 1, 3
• Short-term glucocorticoids (≤3 months) can be used as bridge therapy in CTD-ILD (excluding systemic sclerosis-ILD), but long-term use is discouraged due to toxicity 1, 3

Systemic Sclerosis-Associated ILD (SSc-ILD)

Glucocorticoids are strongly recommended against as first-line therapy for SSc-ILD due to the risk of precipitating scleroderma renal crisis. 1, 3

• First-line options: mycophenolate (comparable outcomes to cyclophosphamide with superior tolerability), azathioprine, rituximab, cyclophosphamide, tocilizumab, or nintedanib 1, 3
• Tocilizumab is conditionally recommended for SSc-ILD and mixed connective tissue disease-ILD 1
• Nintedanib is conditionally recommended as adjunct first-line therapy for SSc-ILD 1, 3

Idiopathic Inflammatory Myopathy-Associated ILD (IIM-ILD)

• First-line options: mycophenolate, azathioprine, rituximab, cyclophosphamide, JAK inhibitors, or calcineurin inhibitors 1, 3
• Intravenous immunoglobulin (IVIG) is conditionally recommended, especially when rapid improvement is needed (e.g., severe respiratory muscle weakness) 3

Rapidly Progressive ILD (RP-ILD)

Pulse intravenous methylprednisolone is conditionally recommended as first-line therapy for RP-ILD due to its rapid onset of action, typically followed by high-dose oral prednisone combined with other immunosuppressive agents (rituximab, cyclophosphamide, IVIG, mycophenolate, calcineurin inhibitors, or JAK inhibitors). 3

Medications to Avoid

• Leflunomide, methotrexate, TNF-inhibitors, and abatacept are conditionally recommended against as first-line treatments for any ILD subtype due to potential pulmonary toxicity 1, 3
• Pirfenidone is conditionally advised against as first-line agent for systemic-autoimmune-related ILD (SARD-ILD) 1

Progressive Pulmonary Fibrosis (PPF) Definition and Management

PPF is defined by at least two of the following within 12 months without alternative explanation:

1. Worsening respiratory symptoms
2. Absolute FVC decline >5% predicted OR absolute DLCO decline >10% predicted
3. Radiological progression (new or increased traction bronchiectasis, new ground-glass opacities, new honeycombing, or greater extent/thickness of reticular abnormality) 1, 3

• When PPF develops despite immunosuppression, adding nintedanib to the existing regimen is conditionally recommended rather than switching immunosuppressive agents 3
• Antifibrotic therapy with nintedanib or pirfenidone is recommended for PF-ILD regardless of underlying ILD subtype 1, 4

Supportive Care and Symptom Management

Oxygen Therapy

• Supplemental oxygen for patients desaturating <88% during 6-minute walk test reduces dyspnea and enhances quality of life 1, 4

Pulmonary Rehabilitation

• Structured exercise therapy improves 6-minute walk distance and health-related quality of life 1, 4

Cough Management

• Prior to attributing cough to ILD, systematically evaluate for gastro-esophageal reflux disease (GERD), asthma, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome 3
• GERD is a common reversible contributor, especially in systemic sclerosis with esophageal dysmotility 3
• For refractory ILD-associated cough, consider gabapentin or multimodality speech-pathology therapy 3
• Low-dose opiates (e.g., slow-release morphine 5 mg twice daily) may be used for symptom control in palliative-care setting 3

Pulmonary Hypertension

• In patients with end-stage fibrotic ILD and pulmonary hypertension, inhaled treprostinil improves walking distance and respiratory symptoms 4, 6

Follow-Up and Monitoring

Serial pulmonary function tests (spirometry and DLCO) should be performed every 3-6 months during the first year after diagnosis, then annually if stable. 1, 3

• A ≥5% decline in FVC over 12 months is associated with approximately 2-fold increase in mortality, warranting prompt treatment escalation 1, 4
• Follow-up HRCT is recommended 2-3 years after baseline scan to assess radiologic progression 1, 3
• In high-risk patients (definite fibrosis, extensive radiographic abnormalities, abnormal PFTs, family history, older age, or smoking), perform earlier HRCT at 12 months 1, 3
• Ambulatory desaturation testing every 3-12 months for monitoring 1

Lung Transplant Referral

Patients with elevated risk of mortality should be referred for lung transplantation at the time of diagnosis, before clinical deterioration renders them ineligible. 1, 3

• After lung transplant, patients with ILD have median survival of 5.2-6.7 years compared to <2 years in advanced ILD patients who do not undergo transplant 4

Critical Pitfalls to Avoid

• Never use immunosuppression for IPF; antifibrotic agents are the only evidence-based therapy 3
• Never use high-dose glucocorticoids in systemic sclerosis-ILD due to risk of scleroderma renal crisis 3
• Never attribute cough or dyspnea solely to ILD without first excluding cardiac disease, asthma, GERD, and post-nasal drainage 1, 3
• Do not dismiss interstitial lung abnormalities as clinically insignificant even in asymptomatic patients, as they are associated with 66% increased risk of death and progression risk regardless of symptoms 1
• Up to 10% of ILD patients have normal chest X-rays; chest radiography alone is insufficient 1
• Co-management with pulmonologists is advised for initiating ILD treatment, especially to determine need for therapy in asymptomatic patients with stable, mild disease 1, 3